DESIGN AND INVITRO CHARACTERIZATION OF METFORMIN LOADED RESEALED ERYTHROCYTES
Objective: Metformin is an oral antidiabetic drug in the biguanide class. It is the first-line drug of choice for the treatment of type 2 diabetes. The
objective of this study was to retard the release of metformin using carrier erythrocyte for getting a parenteral slow release depot formulation.
Methods: The study retards the release of metformin by encapsulating in carrier erythrocyte. Endocytosis is the method used for the encapsulation
of the drug metformin.
Results: The optimized formulation shows 98.34% of drug release within 12 days. From the in vitro release data, zero order kinetic graph shows the
best fit graph. % cell recovered was found to be 73-78% and it suggests that the loading technique was less destructive.
Conclusion: The optimized formulation is a perfect carrier for the parenteral slow release depot of metformin.
Keywords: Resealed erythrocytes, Cross-linking, Cell recovery, Endocytosis, Slow release depot formulation.
2. Tan QY, Li HD, Zhu RH, Zhang QZ, Zhang J, Peng WX. Tolerability and pharmacokinetics of ranolazine following single and multiple sustained-release doses in Chinese healthy adult volunteers: A randomized, open-label, Latin square design, phase I study. Am J Cardiovasc Drugs 2013;13(1):17-25.
3. Davidson MB, Peters AL. An overview of metformin in the treatment of Type 2 diabetes mellitus. Am J Med 1997;102(1):99-110.
4. Fang RH, Hu CM, Zhang L. Nanoparticles disguised as red blood cells to evade the immune system. Expert Opin Biol Ther 2012;12(4):385-9.
5. Ashutosh M. Resealed erythrocytes: An engineering approach for drug delivery and drug targeting. Int J Pharm Pharm Sci 2016;8(5):376-84.
6. Pragya, Vaibhav R. Resealed erythrocytes: A promising drug delivery. Int J Pharm Pharm Sci 2012;4(3):75-82.
7. Park KM, Mrsny RJ. Controlled drug delivery: Present and future. In: Controlled Drug Delivery: Designing Technologies for the Future. Series, 752. Washington, DC: American Chemical Society; 2000. p. 2-3.
8. Schriei SL, Bensch KG, Johnson M, Junga I. Energized endocytosis in human erythrocyte ghosts. J Clin Invest 1975;56(1):8-22.
9. Corey EJ, CzakÃ³ B, KÃ¼rti L. Molecules and Medicine. Hoboken, NJ: Wiley; 2012.
10. Dowler BC, editor. Endocytosis: Structural Components, Functions and Pathways. Hauppauge, NY: Nova Science Publishers; 2010.
11. Patel PD, Dand N, Hirlekar RS, Kadam VJ. Drug loaded erythrocytes: As novel drug delivery system. Curr Pharm Des 2008;14(1):63-70.
12. Dodov MG, Simonoska M, Goracinova K. Formulation and characterization of topical liposome gel bearing lidocaine HCl. Bull Chem Technol Maced 2005;24(1):59-65.
13. Nayak UY, Gopal S, Mutalik S, Ranjith AK, Reddy MS, Gupta P, et al. Glutaraldehyde cross-linked chitosan microspheres for controlled delivery of zidovudine. J Microencapsul 2009;26(3):214-22.
14. Karbiner MS, Sierra L, Minahk C, Fonio MC, Bruno MP, Jerez S. The role of oxidative stress in alterations of hematological parameters and inflammatory markers induced by early hypercholesterolemia. Life Sci 2013;93(15):503-8.
15. Vyas SP, Jain SK. Preparation and in vitro characterization of a magnetically responsive ibuprofen-loaded erythrocytes carrier. J Microencapsul 1994;11(1):19-29.
16. HortolÃ P. SEM examination of human erythrocytes in uncoated bloodstains on stone: Use of conventional as environmental-like SEM in a soft biological tissue (and hard inorganic material). J Microsc 2005;218:94-103.
17. Larson MC, Woodliff JE, Hillery CA, Kearl TJ, Zhao M. Phosphatidylethanolamine is externalized at the surface of microparticles. Biochim Biophys Acta 2012;1821(12):1501-7.
The publication is licensed under CC By and is open access. Copyright is with author and allowed to retain publishing rights without restrictions.